as 05-20-2024 10:34am EST
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Founded: | 2004 | Country: | United States |
Employees: | N/A | City: | ALAMEDA |
Market Cap: | 7.8B | IPO Year: | 2015 |
Target Price: | $293.83 | AVG Volume (30 days): | 384.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 2.37 | EPS Growth: | 1294.12 |
52 Week Low/High: | $180.93 - $348.67 | Next Earning Date: | 05-07-2024 |
Revenue: | $1,095,779,000 | Revenue Growth: | 23.87% |
Revenue Growth (this year): | 18.75% | Revenue Growth (next year): | 16.63% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $216.28 | 220 | $47,581.60 | 64,661 | SEC Form 4 |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $217.02 | 233 | $50,565.66 | 64,428 | SEC Form 4 |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $217.78 | 109 | $23,738.02 | 64,319 | SEC Form 4 |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $219.14 | 24 | $5,259.36 | 64,295 | SEC Form 4 |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $219.84 | 5 | $1,099.20 | 64,290 | SEC Form 4 |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $220.87 | 4 | $883.48 | 64,286 | SEC Form 4 |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $221.77 | 1 | $221.77 | 64,285 | SEC Form 4 |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $223.19 | 3 | $669.57 | 64,282 | SEC Form 4 |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '24 | Sell | $223.71 | 1 | $223.71 | 64,281 | SEC Form 4 |
Kassing Don W. | PEN | Director | Apr 1 '24 | Sell | $223.18 | 170 | $37,940.60 | 1,175 | SEC Form 4 |
Bose Arani | PEN | Director | Mar 4 '24 | Sell | $250.20 | 7,500 | $1,876,500.00 | 164,294 | SEC Form 4 |
Grewal Harpreet | PEN | Director | Jan 3 '24 | Sell | $240.82 | 170 | $40,939.40 | 8,980 | SEC Form 4 |
Sarna Surbhi | PEN | Director | Jan 2 '24 | Sell | $247.68 | 85 | $21,052.80 | 2,295 | SEC Form 4 |
O'Rourke Bridget | PEN | Director | Nov 30 '23 | Sell | $226.41 | 150 | $33,961.50 | 4,214 | SEC Form 4 |
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
GuruFocus.com
4 days ago
Zacks
11 days ago
Simply Wall St.
11 days ago
Insider Monkey
12 days ago
Zacks
12 days ago
GuruFocus.com
13 days ago
Associated Press Finance
13 days ago
PR Newswire
13 days ago